Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P41002

UPID:
CCNF_HUMAN

ALTERNATIVE NAMES:
F-box only protein 1

ALTERNATIVE UPACC:
P41002; B2R8H3; Q96EG9

BACKGROUND:
The protein Cyclin-F, known alternatively as F-box only protein 1, is integral to the ubiquitin proteasome system (UPS). It mediates the degradation of various proteins critical for cell cycle progression and genome stability. By targeting proteins for ubiquitination and subsequent degradation, Cyclin-F regulates key cellular processes such as centrosome reduplication, dNTP pool maintenance, and genome integrity, thereby preventing cell cycle anomalies and genomic instability.

THERAPEUTIC SIGNIFICANCE:
Implicated in the pathogenesis of Frontotemporal dementia and/or amyotrophic lateral sclerosis 5, Cyclin-F's dysfunction highlights its potential as a therapeutic target. Exploring Cyclin-F's mechanisms could lead to groundbreaking treatments for these and potentially other neurodegenerative disorders, emphasizing the importance of research in this area.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.